Welcome to our dedicated page for Envista Holdings news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings stock.
Envista Holdings Corporation reports recurring developments as a global dental products company serving dental professionals through consumables, technologies, equipment and services. Its public updates center on quarterly results, core sales trends, adjusted earnings measures, cash flow, share repurchase activity and management presentations at healthcare conferences.
Company news also covers product and brand activity across DEXIS, Kerr, Nobel Biocare and Ormco, including dental implants, orthodontics, digital imaging, restorative and endodontic solutions. Recent product announcements include Kerr Dental's ZenSeal Pro with ZenSave Tips, reflecting Envista's focus on dental workflow, treatment technology and clinician-facing product commercialization.
Envista (NVST) will participate in the Baird 2026 Global Healthcare Conference via a fireside chat on Tuesday, September 15, 2026, from 9:40 to 10:10 AM ET.
A live audio webcast and archived replay will be available in the Investors section of Envista’s website at https://investors.envistaco.com/ for those wishing to follow the event.
Envista (NYSE: NVST) reported second quarter 2026 sales of $730.5 million, reflecting 5.0% core sales growth versus Q2 2025. GAAP net income was $53.7 million with GAAP diluted EPS of $0.33, while adjusted diluted EPS rose to $0.41, up 58% year-on-year.
Adjusted EBITDA reached $107.7 million, up 28% year-on-year, with an adjusted EBITDA margin of 14.7%, an improvement of 230 bps. Specialty Products & Technologies delivered $471.0 million in sales and 3.1% core growth; Equipment & Consumables reported $259.5 million in sales and 8.5% core growth.
Operating cash flow was $119.2 million and free cash flow was $105.1 million, both above the prior year. Envista repurchased 2.4 million shares for approximately $59 million, leaving $283 million of remaining authorization. Based on first-half performance, the company raised 2026 guidance for core sales growth, adjusted EBITDA growth, and adjusted EPS.
Envista (NYSE: NVST) will host an Investor Day on Thursday, September 17, 2026, from 9:00 a.m. to noon EDT, featuring a management presentation and Q&A. The event will be webcast live with a replay available via the Events and Presentations section of investors.envistaco.com.
According to Envista, in-person attendance requires advance registration by contacting IR@envistaco.com. Envista operates a global portfolio of more than 30 dental brands, including DEXIS, Kerr, Nobel Biocare, and Ormco.
Envista (NYSE: NVST) plans to report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host an earnings conference call that day at 2:00 PM PT, with a webcast, slide presentation, and one-year replay available in the Investors section of its website.
Henry Schein (Nasdaq: HSIC) elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus.
Daniel brings decades of healthcare and industrial leadership, including 14 years as Executive Vice President at Danaher (NYSE: DHR) overseeing multiple segments, such as its dental portfolio, and board service at Envista (NYSE: NVST). Company leadership highlighted his understanding of Henry Schein’s business and markets as important for advancing its long-term strategy and integrated healthcare solutions platform.
Envista (NYSE: NVST) reported Q1 2026 results for the quarter ended April 3, 2026. Sales were $706 million with core sales growth of 9.5%. GAAP net income was $39 million; adjusted EBITDA was $99 million (+25% YoY) and adjusted EPS was $0.36 (+50% YoY).
Operating cash flow was negative $3 million and free cash flow was negative $16 million. The Board authorized an incremental $300 million share repurchase program through December 31, 2029. Full‑year 2026 guidance was reaffirmed.
Kerr Dental (NVST) launched ZenSeal Pro with ZenSave Tips on April 16, 2026, a bioceramic sealer system designed to improve delivery efficiency and reduce waste.
The ZenSave Tips cut material waste by 33.5% versus other high-flow BC sealers and enable an average of 57 canals per 1.5 g syringe versus ~48 with comparator systems, with the company estimating over $1,500 in potential annual savings for some practices. ZenSeal Pro is heat compatible, highly flowable, radiopaque, has a pH >11, and supports multiple obturation techniques.
Kerr Dental (NASDAQ:NVST) launched Demi™ Pro on April 16, 2026, a cordless curing light engineered for ergonomics, 360° access, deeper cures, and safety features.
The device highlights a rotatable low-profile tip, integrated radiometer, broad-spectrum output (~380–515 nm), and optional transillumination for chairside assessment.
Envista (NYSE: NVST) will report first quarter 2026 results on Wednesday, May 6, 2026 and will hold a conference call the same day at 2:00 PM PT. The call will last about one hour and will be webcast on the company investor website with slides and a replay available for one year.
Investors can access the call by dialing the provided U.S. and international numbers and referencing Conference ID #51461; presentation materials will be posted to the Investors section before the call.
Envista (NYSE: NVST) reported Q4 2025 and full-year results on Feb 5, 2026. Q4 sales were $751M with 10.8% core sales growth; GAAP diluted EPS was $0.20 and adjusted diluted EPS was $0.38 (+58% YoY). Adjusted EBITDA was $111M (+22% YoY) with a 14.8% margin (+90 bps).
FY 2025 sales were $2,719M with 6.5% core growth, adjusted diluted EPS $1.19 (+63% YoY), adjusted EBITDA $372M (+26% YoY), and free cash conversion 114%. Share repurchases totaled $166M in 2025. 2026 guidance: core sales growth 2–4%, adjusted EBITDA growth 7–13%, adjusted diluted EPS $1.35–$1.45.